Date:10/19/2009

(112) (285) (361) Other, net (4) 16 (13) (57) --- --- --- --- Income (loss) before income taxes 250 (68) 333 494 Income tax expense (benefit) 50 (6) (12) 136 ---- ---- ---- ---- Net income (loss) $200 $(62) $345 $358 ==== ==== ==== ==== Net income (loss) per common share - basic $0.13 $(0.04) $0.23 $0.24 Net income (loss) per common share - assuming dilution $0.13 $(0.04) $0.23 $0.24 Weighted-average shares outstanding ------------------- Basic 1,509.3 1,500.9 1,507.0 1,497.5 Assuming dilution 1,520.2 1,500.9 1,514.4 1,504.4

                              BOSTON SCIENTIFIC CORPORATION
                          CONDENSED CONSOLIDATED BALANCE SHEETS

                                                   September 30,  December 31,
    in millions, except share data                       2009        2008
    ------------------------------                       ----        ----
                                                    (Unaudited)
    ASSETS
    Current assets:
     Cash and cash equivalents                             $1,381      $1,641
     Trade accounts receivable, net                         1,431       1,402
     Inventories                                              942         853
     Deferred income taxes                                    825         911
     Prepaid expenses and other current assets                383         645
                                                       
'/>"/>
SOURCE  Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
Related medicine technology :

1. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
2. Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Covered Stents
3. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
4. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
5. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
6. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress
8. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
9. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials